Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200913 | 0.79 | POLB (0.49) | POLBSMN1; SMN2 | |
| SCHEMBL14048826 | 0.79 | POLB (0.32) | POLBCA12CA1CA2CA9 | |
| SCHEMBL389987 | 0.79 | POLB (0.49) | POLBSMN1; SMN2 | |
| SCHEMBL4109077 | 0.79 | POLB (0.49) | POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3055388 | 0.78 | POLB (0.47) | POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2337448 | 0.78 | POLB (0.47) | POLBSMN1; SMN2 | |
| SCHEMBL11100722 | 0.78 | CYP3A4 (0.41) | POLBALDH1A1SMN1; SMN2RAB9A | |
| Hydrochloric Acid SCHEMBL5159954 | 0.78 | POLB (0.47) | POLBSMN1; SMN2 | |
| SCHEMBL8385960 | 0.76 | POLB (0.36) | POLBALDH1A1RAB9A | |
| SCHEMBL678254 | 0.76 | POLB (0.36) | POLBALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321177-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4223299-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3705125-B1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-05-12 | — | — | US | disclosed |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-01-13 | — | — | US | disclosed |
| US-11110174-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200297853-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2020-09-24 | — | — | US | disclosed |
| EP-3705125-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20130317080-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2616543-A1 | MODIFIED iRNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450467-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012037254-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2229186-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | POLB 297/4885CA12 1421/4885CA1 2840/4885 |
| US-20200297853-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | POLB 1646/4885CA12 17/4885CA1 242/4885 |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | HAVCR2, B3GAT3, CSGALNACT1 | POLB 2228/4885CA12 109/4885CA1 1076/4885 |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | POLB 1646/4885CA12 17/4885CA1 242/4885 |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | HAVCR2, B3GAT3, CSGALNACT1 | POLB 2228/4885CA12 109/4885CA1 1076/4885 |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | POLB 297/4885CA12 1421/4885CA1 2840/4885 |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | POLB 1646/4885CA12 17/4885CA1 242/4885 |
| US-11110174-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | POLB 1646/4885CA12 17/4885CA1 242/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | POLB 297/4885CA12 1421/4885CA1 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.